Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...
Expectations around Journavx are high. With the U.S. still mired in an overdose crisis that’s killed hundreds of thousands of people, Vertex is positioning its medicine as a valuable alternative ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
During a quarterly earnings presentation (PDF) on Monday, Vertex executives said the company expects to begin shipping Journavx by the end of this month. In the early phase of the launch ...
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
5don MSN
U.S.-based companies are dragging down the major stock market indexes. Here's why four Motley Fool contributors think chip ...
MoneyWeek on MSN2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback